S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:KTRA

Kintara Therapeutics (KTRA) Stock Price, News & Analysis

$0.09
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$0.09
$0.09
50-Day Range
$0.08
$0.15
52-Week Range
$0.08
$5.98
Volume
3.79 million shs
Average Volume
11.52 million shs
Market Capitalization
$3.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Kintara Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
5.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Kintara Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.48) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.12 out of 5 stars

KTRA stock logo

About Kintara Therapeutics Stock (NASDAQ:KTRA)

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

KTRA Stock Price History

KTRA Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Kintara Therapeutics Bounces Back
Kintara Therapeutics Inc (KTRA)
MyMD Pharmaceuticals Inc (0A8D)
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Kintara Therapeutics Inc (3DMA.BE)
Kintara Therapeutics Inc KTRA
Kintara Therapeutics Non-GAAP EPS of -$9.27
KTRA - Kintara Therapeutics, Inc.
See More Headlines
Receive KTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KTRA
Employees
2
Year Founded
N/A

Profitability

Net Income
$-14,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($5.86) per share

Miscellaneous

Free Float
37,152,000
Market Cap
$3.49 million
Optionable
Not Optionable
Beta
0.59
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Jeffrey A. Bacha B.Sc. (Age 56)
    M.B.A., Founder
  • Mr. Greg A. Johnson
    Acting Head of Operations

KTRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kintara Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KTRA shares.
View KTRA analyst ratings
or view top-rated stocks.

How have KTRA shares performed in 2024?

Kintara Therapeutics' stock was trading at $0.1696 at the start of the year. Since then, KTRA stock has decreased by 47.2% and is now trading at $0.0895.
View the best growth stocks for 2024 here
.

When is Kintara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our KTRA earnings forecast
.

How were Kintara Therapeutics' earnings last quarter?

Kintara Therapeutics, Inc. (NASDAQ:KTRA) released its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.24) earnings per share (EPS) for the quarter.

When did Kintara Therapeutics' stock split?

Kintara Therapeutics shares reverse split before market open on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Kintara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN).

How do I buy shares of Kintara Therapeutics?

Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KTRA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners